Press release
Global RNAi Technology Market: Opportunities in Targeted Therapeutics | Major Companies are Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Atalanta Therapeutics.
RNAi Technology Market
The RNAi Technology Market takes center stage in DataM Intelligence's latest comprehensive research, where industry experts deliver cutting-edge analysis powered by robust data analytics and strategic market intelligence. This groundbreaking study dives deep into the competitive ecosystem, spotlighting market leaders and their innovative approaches to product development, competitive pricing models, financial performance, and expansion strategies. The research unveils critical market forces, competitive positioning, and breakthrough trends that will define the industry's trajectory in the coming years, providing stakeholders with actionable intelligence to navigate this rapidly evolving marketplace.
Unlock exclusive insights with our detailed sample report (Please enter your Corporate Email ID to get priority access):- https://datamintelligence.com/download-sample/rnai-technology-market?rk
RNAi Technology (RNA interference technology) is a biological process used to silence specific gene expression through the introduction of double-stranded RNA (dsRNA) into a cell. This dsRNA triggers a cellular mechanism that degrades complementary messenger RNA (mRNA) molecules, preventing the translation of the targeted gene into protein. RNAi is a powerful tool for research and therapeutic applications, enabling the study of gene function, the development of gene therapies, and the treatment of various diseases, including cancer and genetic disorders, by selectively inhibiting disease-causing genes.
RNAi Technology Market: Industry Giants and Emerging Leaders:
Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Atalanta Therapeutics, Phio Pharmaceuticals, Benitec Biopharma, Novartis AG, AstraZeneca, Silence Therapeutics, Arbutus Biopharma and Sylentis S.A
RNAi Technology Industry News:
On May 18, 2023, Phio Pharmaceuticals Corp., a biotechnology company in the development stage with a proprietary INTASYL RNAi platform, announced pre-clinical data demonstrating that using INTASYL to silence CBL-B and TIGIT can enhance the anti-tumor response of natural killer (NK) cells, leading to more effective cell therapy for cancer treatment.
On April 26, 2023, Regeneron Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. reported promising preliminary results from the ongoing single ascending dose phase of the ALN-APP Phase 1 study. This investigational RNAi therapy, known as Aln-APP, targets amyloid precursor protein (APP) and is being developed for the treatment of cerebral amyloid angiopathy (CAA) and Alzheimer's disease.
On January 5, 2023, Orbit Identification Limited, a leader in identifying therapeutic peptide hits, entered into a master service agreement with SanegeneBio Inc. (Sanegene), a start-up focused on developing new RNAi-based therapies. The collaboration aims to discover effective delivery methods for various RNA therapies to target specific tissues and effectively silence disease-causing genes.
Research Methodology
Our comprehensive research approach leverages a dual-methodology framework that seamlessly integrates qualitative insights with quantitative data analysis to deliver robust market intelligence. The process begins with extensive secondary research, where we meticulously collect information from authoritative industry publications, proprietary databases, and verified market sources. This foundation is strengthened through targeted primary research initiatives, including strategic surveys and in-depth interviews with industry veterans, market experts, and key stakeholders.
Speak to Our Senior Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/rnai-technology-market
Segment Covered in the RNAi Technology Market:
By Application: Drug discovery and Development, Therapeutics, Drug Delivery, Agriculture, Others
By Type: Micro RNA, Small interfering RNA
By End User: Research and Academic Laboratories, Diagnostic Laboratories
This Report Covers:
✔ Go-to-market Strategy.
✔ Neutral perspective on the market performance.
✔Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, Market Access, and other significant analysis, as well as development status.
✔Customized regional/country reports as per request and country level analysis.
✔ Potential & niche segments and regions exhibiting promising growth covered.
✔ Top-down and bottom-up approach for regional analysis
Regional Analysis for RNAi Technology Market:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Frequently asked questions:
➠ What is the global sales value, production value, consumption value, import and export of RNAi Technology market?
➠ Who are the global key manufacturers of the RNAi Technology Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?
➠ What are the RNAi Technology market opportunities and threats faced by the vendors in the global RNAi Technology Industry?
➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?
➠ What focused approach and constraints are holding the RNAi Technology market?
➠ What are the different sales, marketing, and distribution channels in the global industry?
Stay informed with the latest industry insights-start your subscription now: https://www.datamintelligence.com/reports-subscription
Looking For Detailed Full Report? Get it here: https://datamintelligence.com/buy-now-page?report=rnai-technology-market
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global RNAi Technology Market: Opportunities in Targeted Therapeutics | Major Companies are Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Atalanta Therapeutics. here
News-ID: 4069942 • Views: …
More Releases from DataM Intelligence 4market Research LLP
The Future of Chemotherapy: Innovations in Liposomal Doxorubicin Therapy | Top C …
The Global Liposomal Doxorubicin Market reached US$ 1.33 billion in 2024 and is expected to reach US$ 2.23 billion by 2033, growing at a CAGR of 6.1% during the forecast period 2025-2033.
The Liposomal Doxorubicin Market takes center stage in DataM Intelligence's latest comprehensive research, where industry experts deliver cutting-edge analysis powered by robust data analytics and strategic market intelligence. This groundbreaking study dives deep into the competitive ecosystem, spotlighting market…
Digital Therapeutics Market: Opportunities in Mental Health and Diabetes Care | …
The global digital therapeutics market reached US$ 5.7 billion in 2023 and is expected to reach US$ 27.3 billion by 2031, growing at a CAGR of 21.6% during the forecast period 2024-2031.
The Digital Therapeutics Market takes center stage in DataM Intelligence's latest comprehensive research, where industry experts deliver cutting-edge analysis powered by robust data analytics and strategic market intelligence. This groundbreaking study dives deep into the competitive ecosystem, spotlighting market…
Thalassemia Treatment Market Trends: Innovations in Blood Transfusion and Chelat …
The Thalassemia Treatment Market is expected to grow at a CAGR of 10.5% during the forecast period 2024-2031.
The Thalassemia Treatment Market takes center stage in DataM Intelligence's latest comprehensive research, where industry experts deliver cutting-edge analysis powered by robust data analytics and strategic market intelligence. This groundbreaking study dives deep into the competitive ecosystem, spotlighting market leaders and their innovative approaches to product development, competitive pricing models, financial performance, and…
Nasal Polyps Treatment Market Dynamics: Key Players and Strategic Developments | …
Nasal Polyps Treatment Market is growing at a CAGR of 5.7% in the forecast period (2024-2031)
The Nasal Polyps Treatment Market takes center stage in DataM Intelligence's latest comprehensive research, where industry experts deliver cutting-edge analysis powered by robust data analytics and strategic market intelligence. This groundbreaking study dives deep into the competitive ecosystem, spotlighting market leaders and their innovative approaches to product development, competitive pricing models, financial performance, and…
More Releases for RNA
Global RNA Analysis/Transcriptomics Market Report
The Global RNA Analysis / Transcriptomics Market is projected to expand at a CAGR of 12.5% during the forecast period, to hit USD 8.1 Billion by 2026, according to a recent market report compiled by Global Market Estimates. Due to the rising need for personalized medicines, the demand for RNA Analysis / Transcriptomics is expected to raise the market demand.
Browse 156 Market Data Tables and 112 Figures spread through 175…
Cancer RNA Expression Market to Reap Excessive Revenues by 2028(By sequencing te …
Worldwide cancer is one of the leading cause of death and effective way of treating it still looks unaccomplished in most parts of the world. The factors which influence the successful treatment of cancer are different depending on the stage of diagnosis, treatment availability and availability of trained healthcare professionals coupled with high economic burden of the disease. The gene expression of cancerous cells varies by cancer type and may…
Senior experts from Exicure, Roche, GSK, BioNTech RNA Pharmaceuticals & MiNA The …
With less than 4 weeks until SMi’s 10th annual RNA Therapeutics event (http://www.therapeutics-rna.com/openpr) opens its doors in London, UK next month, registration will soon be closing and delegate places are becoming increasingly limited.
Over the course of 2 focused days, attendees will be able to have an exclusive look into key developments in oligonucleotide therapeutics, mRNA technology, delivery mechanisms, and much more, led by industry leaders, scientific pioneers, and academics exploring…
RNA Therapy Improves Vision in Child Blindness, hear more about recent developme …
SMi Reports: In light of recent developments in the field of RNA Therapy, SMi’s 10th Annual RNA Therapeutics is set to deliver the latest advancements in February this year.
Leber congenital amaurosis (LCA), one of the most common causes of blindness in children, has been the subject of successful RNA therapy as researchers at the University of Pennsylvania recently published new data showing the success of the new therapy which improved…
New Confirmed Delegates & Speakers for RNA Therapeutics
SMi are thrilled to welcome Dr. James Hamilton, Vice President, Head of Clinical Development, Arrowhead Pharmaceuticals onto the speaker panel RNA Therapeutics 2018!
Dr. James Hamilton is currently responsible for all aspects of clinical trial design, implementation and execution. In this role, Dr. Hamilton managed the ARC-520 and ARC-AAT global programs through Phase 2 of development. Previously, Dr. Hamilton was Medical Director and Head of Corporate Development at Arrowhead. He led…
Introducing the 9th Annual RNA Therapeutics 2018
As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion.
One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo and in-vitro models, hear key case studies on the development on the latest delivery systems and…
